No peptide sold over the counter or on the grey market for gut healing has been tested against a placebo for repairing the gut lining, the single layer of cells that keeps what you eat out of your bloodstream. Collagen peptides, the most-searched option, rest on one 8-week study with no placebo group that 14 of 40 recruited women finished. BPC-157, the most-marketed option, has a large animal literature and no published human efficacy trial for any condition. The one compound here with randomised human evidence is teduglutide, a prescription copy of the gut hormone GLP-2, tested against placebo in 86 people; it grew gut lining and cut intravenous feeding needs, and it is approved for short bowel syndrome after surgical removal of intestine, not for bloating.
Peptides commonly discussed for gut healing
Safety: Blood in the stool, black or tarry stools, unintentional weight loss, pain that wakes you at night, iron-deficiency anaemia, or any new gut symptom after age 45 needs a clinician before any compound, because those are the patterns that point to bleeding, coeliac disease, inflammatory bowel disease or cancer. BPC-157 and KPV are not FDA-approved for any use and have no published human safety data; teduglutide is prescription-only and its US label requires colonoscopy monitoring for polyps because it stimulates gut lining growth. Nothing on this page is a dose recommendation or a diagnosis, and none of it replaces treatment for inflammatory bowel disease. This page is educational, was drafted with AI assistance, and has not been reviewed by a clinician.
Where to buy
Where to get peptides for gut healing
BPC-157
Buy at Swiss Chems →Save 10% at checkout with code tcwisiiu
Some links are affiliate links — we may earn a fee at no extra cost to you. Most peptides aren't FDA-approved — consult a qualified clinician and check your local laws before purchasing.
The gut peptide with the biggest research literature has no published human trial, and the one compound on this page that does have a randomised trial is a prescription drug for a condition you almost certainly do not have. The drugs that already work on the gut turn damage and inflammation down. None of them speed repair. Faster repair is what gut peptides claim, and in people that claim has never been tested against a placebo. BPC-157's case is rat and mouse work 2. KPV's is human cell experiments and two mouse colitis models 5. Collagen peptides, the most-searched of the four, have one open-label study with 14 finishers behind them 1. Teduglutide, a lab-made copy of the gut hormone GLP-2, has a randomised trial in 86 adults and an FDA approval that covers short bowel syndrome only 3.
Gut healing is three problems, and each compound targets a different one
Sort the field by the problem being solved and the marketing stops blurring together. A lining that has been burned, scraped or made leaky is a repair problem, and leaky gut is the internet's name for it. A colon wall full of activated immune cells is an inflammation problem. A gut that is physically too short after surgery is a surface-area problem. One phrase covers all three. The compounds do not.
| The problem | What it looks like | What gets pitched for it | Best evidence behind that pitch |
|---|---|---|---|
| A damaged or leaky gut lining | Reflux burn, gastritis, damage from anti-inflammatory painkillers, reactions to foods that used to be fine. This is what people online call leaky gut. | BPC-157 | Rat and mouse studies only, and no published human efficacy trial 2 |
| Inflammation in the gut wall | Ulcerative colitis, Crohn's disease, other inflammatory bowel disease symptoms | KPV | Human cell work plus two chemically induced mouse colitis models 5 |
| Lost absorbing surface | Short bowel syndrome after surgical removal of intestine, intestinal failure | Teduglutide, a GLP-2 copy | Randomised placebo-controlled trial in 86 patients 3 |
| General bloating with no diagnosis | Post-meal bloat, irregular stools, normal tests | Collagen peptides | One 8-week single-arm study, 14 completers, no placebo group 1 |
Conventional treatment sits mostly outside all three lanes. Proton pump inhibitors, the acid blockers sold as omeprazole and its relatives, cut stomach acid so damaged tissue is not burned again, and 5-ASA drugs damp inflammation in the colon wall. Both are approved on randomised trial evidence, and both work by removing the insult that caused the damage. Neither speeds repair. The argument for gut peptides is that repair itself can be pushed. In animals it can, and in people it has not been shown.
Are collagen peptides good for gut health?
The entire published human evidence for collagen peptides and digestive symptoms is one study, run digitally in the United States in healthy women with a body mass index above 25. Forty were recruited, 14 completed the full 8 weeks at 20 g a day split into two servings, and 13 of those 14 reported fewer digestive symptoms including bloating 1. There was no placebo group, no blinding and no control for the fact that everyone was tracking their symptoms in an app for nine weeks. The authors are careful about it, concluding that 20 g a day "may reduce bloating and improve mild digestive symptoms in otherwise healthy female adults" 1.
It is one small uncontrolled study, and the gap between it and the phrase "collagen peptides for gut health" on a tub is wide. Collagen is a food protein, and digestion breaks it into amino acids and short fragments the way it breaks down any other protein, so the claim that eating it patches a gut lining needs measuring. Collagen's better-evidenced use is joints, where randomised trials exist, and our joint pain page grades those trials one by one (/peptides-for/joint-pain).
The choice most readers are making
How is BPC-157 supposed to heal the gut, and what has that been shown in?
Gut healing is the original use case for BPC-157. The compound was identified in human gastric juice in the early 1990s by Predrag Sikiric's laboratory in Zagreb, and the founding experiments were rat stomach ulcers that closed faster with it than without. Later rat work extended the same claim to experimental colitis and to gut damage caused by anti-inflammatory painkillers, with restoration of the tight-junction proteins that seal one gut lining cell to the next. Every one of those studies is an animal study.
The clearest recent count covers the musculoskeletal literature. A 2025 systematic review written from an orthopaedic sports medicine angle screened 544 papers from 1993 to 2024 and included 36 that reported mechanism, musculoskeletal outcomes, metabolism or safety. Thirty-five were preclinical and one was clinical, a retrospective note on 12 people with chronic knee pain 2. Gut studies fell outside its search, so it counts what exists in orthopaedics and not the whole BPC-157 file. The same review reports a half-life under 30 minutes, breakdown in the liver, clearance by the kidneys, no adverse effects across several organ systems in animals, and no clinical safety data at all 2. Our half-life explainer carries that 30-minute figure through to why online protocols split doses across the day (/learn/tb-500-bpc-157-half-life), and the same animal repair literature is why BPC-157 tops tendon and injury stacks, graded on our healing page (/learn/best-peptides-for-healing) and our injury recovery page (/peptides-for/injury-recovery).
Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.
One trial does get quoted as human evidence: a phase 2 study of oral BPC-157, coded PL 14736, in ulcerative colitis. The FDA's own 2026 review of the compound describes it as testing oral doses of 0.4 mcg and 0.4 mg with dose-dependent improvement, and notes that it has never been published as a standalone clinical paper, so nobody outside the group that ran it can check the numbers. Unpublished results are the weakest form of human evidence, and a vendor page quoting them is quoting something you cannot read.
Is GLP-2 the same as GLP-1?
GLP-1 and GLP-2 are sister molecules cut from the same parent protein by the same cells in the gut wall, and they do different jobs. GLP-1 lowers blood sugar and suppresses appetite, which is the mechanism behind semaglutide (/peptides/semaglutide) and the rest of the weight-loss class (/peptides-for/weight-loss). GLP-2 stimulates growth of the gut lining and tightens barrier function, and it does not cause weight loss. Confusing the two is common enough that people arrive expecting a GLP-2 drug to be a weight-loss drug.
Teduglutide is a modified copy of GLP-2 built to resist the enzyme that normally chews it up within minutes, and it is the one FDA-approved peptide drug on this page. In the STEPS phase 3 trial, 86 adults with short bowel syndrome were randomised to teduglutide at 0.05 mg/kg a day under the skin or placebo for 24 weeks. Twenty-seven of 43 on the drug cut their intravenous feeding volume by more than 20 percent, against 13 of 43 on placebo, and blood citrulline rose, which is a marker of how much gut lining a person has 3.
The earlier pilot is the more instructive one for anyone hoping this generalises. Sixteen patients took teduglutide for 21 days. Absorption improved by 743 g a day of fluid and food weight, and in patients whose bowel had been brought out to an opening on the abdomen, an end stoma, the villi, the finger-like folds that do the absorbing, grew 38 percent taller (p = 0.03). Then the drug was stopped, and the improvements reversed during drug-free follow-up 4. The gut lining responds while the signal is present and drifts back when it is not, which is what to expect from any compound aimed at this tissue.
What KPV does to inflammatory signalling, in cells and in mice
KPV is the last three amino acids of alpha-MSH, a hormone your own body makes. Its mechanism is worked out in unusual detail for a compound with no human data, and the detail explains why KPV is aimed at the colon specifically. Where KPV overlaps with the other anti-inflammatory compounds people stack it with sits on our inflammation page (/peptides-for/inflammation).
How KPV reaches an inflamed colon cell and switches it down
This study indicates that KPV is transported into cells by PepT1 and might be a new therapeutic agent for IBD.Dalmasso G et al., Gastroenterology, 2008 [[5]]
Note the word might. That sentence was written in 2008, and a search of PubMed and ClinicalTrials.gov in August 2026 turns up no human trial of KPV in any condition.
Eighteen years, no human trial. That silence is itself information.
The compounds, graded
| Option | What it does | Human evidence | Status | Verdict |
|---|---|---|---|---|
| Teduglutide (GLP-2 copy) | Signals gut lining cells to grow, slows transit, improves absorption | Randomised, placebo-controlled, 86 patients, 24 weeks 3 | FDA-approved, prescription, short bowel syndrome only | Works, and almost certainly not for you |
| 5-ASA drugs such as mesalamine | Damps inflammation in the colon wall | Approved on randomised trial evidence in ulcerative colitis | FDA-approved, prescription | Standard of care, do not replace it |
| Acid blockers (proton pump inhibitors) | Cut stomach acid so damaged tissue is not burned again | Approved on randomised trial evidence in ulcer and reflux disease | FDA-approved, prescription and over the counter | Removes the insult, does not repair |
| Collagen peptides | Food protein, digested to amino acids and short fragments | One open-label single-arm study, 14 completers, no placebo group 1 | Food supplement, sold freely | Cheap, safe, unproven for this |
| Diet and microbiome work (fibre, removing the driver) | Changes what the gut is exposed to daily | Large and mixed, and specific to the condition being treated | Free to cheap, no regulatory status needed | The boring one with the most upside |
| BPC-157 | Claimed repair of the gut lining via growth-factor and blood-vessel pathways | No published human efficacy trial for any condition; one phase 2 in ulcerative colitis was run and never published | Not FDA-approved; sold as a research chemical | A rat drug being sold to people |
| KPV | Blocks inflammatory signalling inside gut lining and immune cells | None published as of August 2026 5 | Not FDA-approved | Best mechanism story here, no human data |
LL-37 (/peptides/ll-37) and thymosin alpha-1 (/peptides/thymosin-alpha-1) turn up in gut stacks as well, and neither has a published randomised human trial in any gut condition, so they sit a tier below the four compounds above. Readers also arrive asking about the KLOW blend, which packages KPV with other repair peptides in one vial; the card below shows what is in it.
What researchers actually gave, and for how long
The single most-searched question about BPC-157 and the gut is how long to take it. No completed human trial has been published to derive a duration from, so every number in circulation comes from habit. Here is what the studies behind each compound did.
| Study | Species and number | Dose and route | Duration | What was measured |
|---|---|---|---|---|
| Teduglutide, STEPS phase 3 3 | Humans, 86 | 0.05 mg/kg/day, injected under the skin | 24 weeks | 63 percent cut intravenous feeding volume by over 20 percent versus 30 percent on placebo (p = 0.002) |
| Teduglutide pilot 4 | Humans, 16 | 0.03, 0.10 or 0.15 mg/kg/day under the skin | 21 days | Absorption up 743 g/day; villus height up 38 percent (p = 0.03); gains reversed after stopping |
| Collagen peptides 1 | Humans, 14 completers of 40 recruited | 20 g/day by mouth, split into two servings | 8 weeks | Self-reported digestive symptoms, no placebo group |
| KPV in mouse colitis 5 | Mice, two chemically induced colitis models | Added to drinking water | Length of each colitis model | Colitis severity and inflammatory gene expression in the colon |
| BPC-157 in any gut condition | No published human trial | The 250 to 500 mcg/day figure in circulation is not trial-derived | Not established | Nothing published in people |
Practitioner protocols typically run 8 to 12 weeks and then pause, on the reasoning that animal healing curves flatten by then. That reasoning has never been checked against a human outcome. Our dosing page traces the 250 to 500 mcg/day figure back to the animal studies and clinic habits it came from (/learn/bpc-157-dosage-guide), and the case for pausing at all is on the cycling page (/learn/peptide-cycling-protocol). Duration and dose are clinical questions and belong with a clinician who knows your history.
Cost, storage, and what is unknown
What follows describes what grey-market sellers ship and how buyers report handling it. It is not a recommendation to buy or use an unapproved compound, which cannot lawfully be sold or compounded for human use in the US, and none of it has been through the quality controls that apply to a prescription drug. If none of the words in this paragraph are familiar, start with our beginner guide (/learn/peptides-for-beginners). BPC-157 arrives as a freeze-dried white powder in a small glass vial, typically 5 mg, in the tens of dollars. The powder is stable at room temperature for shipping and is kept refrigerated after that; once mixed with bacteriostatic water it is refrigerated and used within weeks, because a peptide in solution degrades. The arithmetic is on our reconstitution guide (/learn/how-to-reconstitute-peptides) and the sterile handling, which matters more than the arithmetic, is on our hygiene guide (/learn/peptide-injection-hygiene-guide). Oral capsules skip both problems and introduce a different one: you cannot see what is in them.
What is known about side effects is thin and lopsided. Animal studies of BPC-157 reported no adverse effects across several organ systems, but those were efficacy experiments and not safety trials, and the 2025 review states plainly that no clinical safety data were found 2. The injection-site irritation and first-week headaches described on forums are self-reports from a channel that collects nothing systematically, so quiet forums are not evidence of safety. For KPV there is nothing at all: a search of PubMed and ClinicalTrials.gov in August 2026 returns no human study in any condition, and the evidence stops at the cell and mouse work in Dalmasso 2008 5. Teduglutide is the exception. Its profile is documented because it went through trials: abdominal pain, nausea, injection-site reactions, colorectal polyp risk, and labelled warnings for intestinal obstruction, gallbladder and pancreatic disease, and fluid overload.
Is BPC-157 legal in the US?
BPC-157 is not FDA-approved for any use, and as of August 2026 no compounding pharmacy may lawfully compound it. The path it has taken is worth stating in order. In September 2023 the FDA placed it in Category 2 of the interim 503A bulk drug substances list, the shelf for substances with significant safety risks; Category 1 is the shelf pharmacies are allowed to compound from. In April 2026 it came off Category 2 because the nominations supporting it were withdrawn, which moved it out of the restricted category without moving it into the permitted one. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it to the 503A bulks list, alongside KPV and four other peptides. The proposal in front of the committee covered use in ulcerative colitis, this page's own subject, and the committee voted yes over the written objection of the FDA's own scientists, who concluded that the evidence did not support effectiveness there. A committee recommendation is advice. The agency still has to run a formal notice-and-comment rulemaking, which takes the better part of a year, and nothing has changed yet about what may lawfully be compounded.
Link · US Food and Drug AdministrationJuly 23-24, 2026 meeting of the Pharmacy Compounding Advisory CommitteeThe FDA's own page for the meeting described above, with the briefing materials the committee read on BPC-157 and KPV and the votes it took.fda.gov Link · US Food and Drug AdministrationBulk drug substances used in compounding under section 503AThe FDA's list of which substances pharmacies may and may not compound, with the category assignments and the reasoning behind them. This list, not this page, is the authority on current status.fda.govFor anyone who competes, the World Anti-Doping Agency's prohibited list puts BPC-157 in class S0, non-approved substances, banned at all times. Sanctions in that class can be non-analytical, based on possession or admission rather than a positive test.
What to rule out before spending money on a gut protocol
Four common causes of chronic gut symptoms are cheap to test for and all four are treatable, which makes them a better first spend than any compound on this page.
- Coeliac disease, tested while you are still eating glutenThe blood test and the biopsy both depend on gluten being in your diet. Cutting gluten first is the single most common way people end up with an unanswerable result and years of uncertainty. If coeliac disease is the answer, removing gluten is the treatment and no peptide substitutes for it.
- Helicobacter pyloriA bacterium that causes gastritis and ulcers, found with a breath or stool test and cleared with antibiotics. Reflux and stomach-burn symptoms that keep coming back deserve this test before a repair-compound protocol.
- Bile acid malabsorptionA frequent and frequently missed cause of chronic loose stools, particularly after gallbladder removal or bowel surgery. It responds to specific prescription binders, and gut lining repair has nothing to do with it.
- A colonoscopy referral if you are over 45 with new symptomsNew bowel symptoms after 45 sit in the age band where screening exists for a reason. Getting the camera first costs a morning and rules out the answer nobody wants to find late.
- Whatever is still doing the damageDaily anti-inflammatory painkillers, heavy alcohol, and untreated chronic stress keep re-inflicting the injury. In rats, BPC-157 reversed painkiller-induced gut damage; asking any compound to outrun ongoing damage in a person is a different proposition, and one nobody has tested.
Why two people on the same protocol report different things
Some of the variation is the gut you started with. FUT2, a gene that decides whether you secrete blood-group sugars into the mucus coating your gut, is the clearest example. Of the 71 adults in the study behind this, 14 secreted none, which is close to the one in five typically seen in people of European descent. Those sugars feed particular bacteria, and the non-secretors carried a different mix of gut bacteria and fewer species overall 6.
The practical consequence is narrow. If you are a non-secretor with ongoing gut symptoms, you are building on a thinner microbiome, which is an argument for putting money and patience into fibre, diet and whatever is driving your symptoms. It is not an argument for choosing a different compound, because no study has tested whether secretor status changes response to any peptide.
Two honest limits go with that. NOD2, the best-known Crohn's disease risk gene, includes a frameshift insertion, a spelling error that shifts everything written after it, and one that consumer DNA arrays generally cannot read. A raw data file showing nothing there has usually not looked. And inflammatory-tone variants such as the common IL6 promoter change, which nudges how much of one inflammatory messenger you make at rest, describe a starting point. Whether they change how anyone reacts to KPV, BPC-157 or teduglutide has never been tested. Our framework page applies the same rule across all 39 peptides: a marker earns a place in a report only when a published human study links it to a measured response (/learn/which-peptides-dna-decision-framework).
One finding here travels further than the rest. Teduglutide grew gut lining while patients took it, and the gains reversed once they stopped 4. Anything aimed at this tissue behaves like a signal you have to keep sending, which is worth knowing before you buy a compound that has never been measured in a person at all. A diagnosis is still the highest-value purchase in this category. Coeliac serology, a Helicobacter pylori breath test and a bile acid test together cost less than a month of grey-market BPC-157, and all three point to a treatment.
Upload your raw DNA data and get all 39 peptides ranked against your markers, with the evidence tier for each stated plainly, including where your file cannot answer the question, as with NOD2, which consumer arrays generally cannot read. No report can predict how you will respond to BPC-157 or KPV, because no study has tested that. Educational use only, and not a diagnostic test.
Get your DNA report- The most-marketed gut peptide has the emptiest human file
BPC-157 was discovered as a gut compound, and the founding experiments plus a large share of the animal literature are gut work. All of the published gut work is in animals, and the one human trial that was run has never been published, so nobody outside the group that ran it can read the numbers. The compound on this page with real randomised human gut evidence, teduglutide, is an approved prescription drug for short bowel syndrome, and it is not what grey-market gut protocols are selling.
Frequently asked questions
How long do people take BPC-157 for gut health?
No trial has established a duration, because no human efficacy trial of BPC-157 has been published for any gut condition. The one phase 2 study in ulcerative colitis that was run has never been published, and a 2025 systematic review of the compound found a single clinical study among 36, on knee pain [[2]]. The 8 to 12 week blocks quoted in online protocols come from practitioner habit and animal healing timelines, and the 250 to 500 mcg/day figure that circulates with them is not trial-derived either. Duration and dose are clinical questions for a clinician who knows your history; our dosing page sets out where each circulating figure came from (/learn/bpc-157-dosage-guide).
Can BPC-157 be taken orally for gut healing?
The unpublished phase 2 trial in ulcerative colitis used an oral formulation, and oral capsules are what most grey-market sellers offer for upper-gut complaints, while injection under the skin is more common in online protocols for other uses. No published human study has compared the two routes for any gut condition, and neither route has published human safety data [[2]]. Route and form are clinical questions and belong with a clinician, not with a vendor page.
Can BPC-157 or KPV treat ulcerative colitis or Crohn's disease?
No. Ulcerative colitis and Crohn's disease are immune-driven conditions treated with 5-ASA drugs, immunomodulators and biologics, and no published trial has tested adding BPC-157 or KPV to that standard care. The supporting research is a mouse colitis experiment for KPV [[5]] and animal work for BPC-157 [[2]]. Anyone considering an addition should raise it with the gastroenterologist who prescribes their treatment, who needs to know what else is being taken.
Do collagen peptides survive digestion and reach the gut lining?
Collagen is a food protein, and digestion breaks proteins into amino acids and short fragments before absorption. Whether enough intact fragments act on the gut lining to change symptoms is the question the research has not answered. The only human study of collagen and digestive symptoms had no placebo group [[1]], so it cannot separate the supplement from time, attention and diary-keeping.
Sources6
- Abrahams M, O'Grady R, Prawitt J. Effect of a daily collagen peptide supplement on digestive symptoms in healthy women: 2-phase mixed methods study. JMIR Formative Research, 2022;6(5):e36339.
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025;21(4):485-495.
- Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS phase 3). Gastroenterology, 2012;143(6):1473-1481.
- Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 2005;54(9):1224-1231.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008;134(1):166-178.
- Wacklin P, Tuimala J, Nikkila J, et al. Faecal microbiota composition in adults is associated with the FUT2 gene determining the secretor status. PLoS One, 2014;9(4):e94863.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
This page is educational and is not medical advice. Peptides are not intended to diagnose, treat, cure, or prevent any disease, and most are not FDA-approved. Talk to a qualified healthcare provider before starting anything. Availability and legal status of peptides vary by jurisdiction.
← All condition guides